Key clinical point: Treatment with tofacitinib, tocilizumab, or tumor necrosis factor inhibitors (TNFi) vs. abatacept did not reduce the risk of developing Alzheimer disease and related dementia (ADRD) in patients with rheumatoid arthritis (RA).
Major finding: The risk for ADRD associated with tofacitinib (adjusted hazard ratio [aHR] 0.90; 95% CI 0.55-1.51), tocilizumab (aHR 0.82; 95% CI 0.55-1.21), and TNFi (aHR 0.93; 95% CI 0.72-1.20) was similar to that with abatacept.
Study details: This was an observational study including 22,569 patients aged ≥65 years with RA from the DREAM study who were treated with tofacitinib, tocilizumab, or TNFi and were propensity score-matched with an equal number of patients treated with abatacept.
Disclosures: The DREAM study is funded by the National Institute on Aging . Several authors reported receiving grants, personal fees, or salary support from or owning stocks in various sources outside the submitted work.
Source: Desai RJ et al. Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying antirheumatic agents. JAMA Netw Open. 2022;5(4):e226567 (Apr 8). Doi: 10.1001/jamanetworkopen.2022.6567